CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) including anti‒programmed death-1 (PD-1) monoclonal antibody and PD-L1 have greatly changed the treatment pattern of advanced and metastatic NSCLC [2–6].